Pathway Bioventures

Pathway Bioventures: A seed-stage life sciences fund investing in innovative biotech for unmet medical needs.

Founded

2018

Competitive Advantages

Beyond capital, Pathway supports entrepreneurs on subsequent financings and capital-efficient de-risking strategies, and introduces portfolio teams to future investors and partners including biotech venture firms and pharmaceutical corporate venture arms. The firm describes its approach as selective, building a deep understanding of each technology and its market value.

Its portfolio financings name co-investors including ARCH Venture Partners, Venrock, Forbion, RTW Investments, Canaan Partners, and Boehringer Ingelheim. Portfolio company Modifi Biosciences was acquired by Merck in 2024, with Pathway Bioventures named among the company's investors in the acquisition announcement.

Source: pathwaybioventures.com

Market Outlook

Pathway invests in precision therapeutics it expects to become standard of care, focusing on genetic medicine - gene therapy, cell therapy, oligonucleotide therapeutics, and RNA or DNA editing - and on targeted therapies such as small molecules, antibodies, and antibody-drug conjugates for molecularly defined patient populations. The firm targets companies addressing major unmet medical needs.

Financing activity across these focus areas is visible in its portfolio: Airna raised a $155 million Series B in April 2025, Axonis Therapeutics announced a $115 million Series A in October 2024, and Cytospire Therapeutics announced an oversubscribed GBP 61 million ($83 million) Series A in May 2026. Cytovale completed a $100 million Series D in October 2024 to expand commercialization of its sepsis diagnostic.

Memo

Pathway Bioventures concentrates on early-stage precision therapeutics, co-investing in seed and Series A rounds within syndicates and targeting companies that address major unmet medical needs. The firm states it looks for technology at the intersection of biology and engineering, with focus areas in genetic medicine and targeted therapies.

Its team combines investment roles with operating and research careers: founder and managing partner Daniel Jacobs holds a PhD and MPH from Yale University with post-doctoral training at Baylor College of Medicine; partner Matt Martin holds a PhD in physics from Carnegie Mellon University and an MBA from the University of Chicago Booth School of Business; venture partner Jacob Segil is a research professor at the University of Colorado Boulder; and strategic advisor Marta New founded Radyus Research.